Literature DB >> 9918089

Fetal cardiac measurements derived by transvaginal and transabdominal cross-sectional echocardiography from 14 weeks of gestation to term.

I Shapiro1, S Degani, Z Leibovitz, G Ohel, Y Tal, E G Abinader.   

Abstract

OBJECTIVE: Most of the routine ultrasound screening in our institution consists of early transvaginal examinations at 14-17 weeks. Complete fetal echocardiography is performed in every case. However, normal values for most fetal cardiac structures at this stage of gestation are not available. Our aim was to construct normal ranges for fetal cardiac structures, derived from cross-sectional echocardiography, at 14-40 weeks of gestation.
DESIGN: A prospective study was performed. The study group consisted of 637 pregnant women referred for a routine sonographic examination. Women with abnormal prenatal or postnatal outcome were not included in the study. Transvaginal examinations were used for 14-17 weeks of gestation. More advanced pregnancies were examined transabdominally.
RESULTS: We constructed normal ranges for the left and right end-diastolic transverse ventricular diameters (n = 637), left/right ventricular ratio (n = 637), aortic root diameter (n = 637), pulmonary artery diameter (n = 637), aortic/pulmonary ratio (n = 490), left and right transverse atrial diameters (n = 201) and left/right atrial ratio (n = 201).
CONCLUSIONS: The results provide the examiner with normal ranges for fetal cardiac structures for the early transvaginal examination. The continuity of all curves from 14 to 40 weeks of gestation allows follow-up of any specific fetus to term.

Entities:  

Mesh:

Year:  1998        PMID: 9918089     DOI: 10.1046/j.1469-0705.1998.12060404.x

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  7 in total

1.  Diagnostic ultrasound features and outcome of restrictive foramen ovale in fetuses with structurally normal hearts.

Authors:  Orhan Uzun; Kadir Babaoglu; Yusuf I Ayhan; Marsham Moselhi; Fran Rushworth; Sue Morris; Bryan Beattie; Jarmilla Wiener; Michael J Lewis
Journal:  Pediatr Cardiol       Date:  2014-03-01       Impact factor: 1.655

2.  Features and outcomes in utero and after birth of fetuses with myocardial disease.

Authors:  Vlasta Fesslova; Maurizio Mongiovì; Salvatore Pipitone; Jelena Brankovic; Laura Villa
Journal:  Int J Pediatr       Date:  2010-10-03

3.  Perinatal changes in size of the fetal great arteries.

Authors:  Hae Soon Kim; Young Mi Hong; Sejung Sohn; Jung Yun Choi
Journal:  Korean Circ J       Date:  2009-10-28       Impact factor: 3.243

4.  Investigating the characteristics of echocardiogram, surgical treatment, chromosome and prognosis for fetal right heart enlargement: A STROBE-compliant article.

Authors:  Lin Liu; Hong-Dan Wang; Cun-Ying Cui; Hui-Mei Yao; Lei Huang; Tao Li; Tai-Bing Fan; Bang-Tian Peng; Lian-Zhong Zhang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

5.  Feasibility of 4D-Spatio Temporal Image Correlation (STIC) in the Comprehensive Assessment of the Fetal Heart Using FetalHQ®.

Authors:  Laura Nogué; Olga Gómez; Nora Izquierdo; Cristina Mula; Narcís Masoller; Josep M Martínez; Eduard Gratacós; Greggory Devore; Fàtima Crispi; Mar Bennasar
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

6.  Cardiac Measurements of Size and Shape in Fetuses With Absent or Reversed End-Diastolic Velocity of the Umbilical Artery and Perinatal Survival and Severe Growth Restriction Before 34 Weeks' Gestation.

Authors:  Greggory R DeVore; Percy Pacora Portella; Edgar Hernandez Andrade; Lami Yeo; Roberto Romero
Journal:  J Ultrasound Med       Date:  2020-10-30       Impact factor: 2.754

7.  Dependency of magnetocardiographically determined fetal cardiac time intervals on gestational age, gender and postnatal biometrics in healthy pregnancies.

Authors:  Peter Van Leeuwen; Silke Lange; Anita Klein; Daniel Geue; Dietrich HW Grönemeyer
Journal:  BMC Pregnancy Childbirth       Date:  2004-04-02       Impact factor: 3.007

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.